MedTrace Logo

Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

NCT07697833 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2026-07-13

No results posted yet for this study

Summary

To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Interventions

DRUG

Vericiguat tablet

Vericiguat 10 mg (titrated from 2.5 mg, to 5 mg, and to 10 mg), on a background of standard of care

DRUG

Placebo

Participants will receive a matching placebo tablet. The placebo will follow the same dosing schedule as the study drug (2.5 mg, 5 mg, and 10 mg) to maintain blinding.

Sponsors & Collaborators

  • Horizon Pharmaceuticals

    collaborator UNKNOWN

  • National Institute of Cardiovascular Diseases, Pakistan

    lead OTHER

Principal Investigators

  • Ghazala Irfan, FCPS · National Institute of Cardiovascular Diseases Karachi, Pakistan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2027-05-15
Completion
2027-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07697833 on ClinicalTrials.gov